BR112012013502A2 - "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos". - Google Patents
"polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos".Info
- Publication number
- BR112012013502A2 BR112012013502A2 BR112012013502A BR112012013502A BR112012013502A2 BR 112012013502 A2 BR112012013502 A2 BR 112012013502A2 BR 112012013502 A BR112012013502 A BR 112012013502A BR 112012013502 A BR112012013502 A BR 112012013502A BR 112012013502 A2 BR112012013502 A2 BR 112012013502A2
- Authority
- BR
- Brazil
- Prior art keywords
- chimeric
- methods
- factor viii
- polypeptides
- hybrid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos. a presente invenção provê métodos de administrar fator viii; métodos de administrar polipeptídeos quiméricos e híbridos compreendendo fator viii; polipeptídeos quiméricos e híbridos compreendendo fator viii; polinucleotídeos codificando tais polipeptídeos quiméricos e híbridos; células compreendendo tais polinucleotídeos, e métodos de produzir tais polipeptídeos quiméricos e híbridos utilizando tais células.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26707009P | 2009-12-06 | 2009-12-06 | |
US28505409P | 2009-12-09 | 2009-12-09 | |
US30159210P | 2010-02-04 | 2010-02-04 | |
US36306510P | 2010-07-09 | 2010-07-09 | |
US37311310P | 2010-08-12 | 2010-08-12 | |
US41092910P | 2010-11-07 | 2010-11-07 | |
US41967610P | 2010-12-03 | 2010-12-03 | |
PCT/US2010/059136 WO2011069164A2 (en) | 2009-12-06 | 2010-12-06 | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012013502A2 true BR112012013502A2 (pt) | 2017-01-10 |
Family
ID=44115536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012013502A BR112012013502A2 (pt) | 2009-12-06 | 2010-12-06 | "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos". |
Country Status (30)
Country | Link |
---|---|
US (5) | US9050318B2 (pt) |
EP (3) | EP2506868B1 (pt) |
JP (7) | JP5903048B2 (pt) |
KR (1) | KR101770849B1 (pt) |
CN (1) | CN102791285A (pt) |
AU (5) | AU2010325787B2 (pt) |
BR (1) | BR112012013502A2 (pt) |
CA (2) | CA2782424C (pt) |
CO (1) | CO6561782A2 (pt) |
CY (2) | CY1119919T1 (pt) |
DK (1) | DK2506868T3 (pt) |
EA (2) | EA025416B1 (pt) |
ES (2) | ES2659888T3 (pt) |
HK (1) | HK1253887A1 (pt) |
HR (2) | HRP20180135T1 (pt) |
HU (1) | HUE036233T2 (pt) |
IL (2) | IL220204B (pt) |
LT (1) | LT2506868T (pt) |
ME (1) | ME02964B (pt) |
MX (2) | MX353233B (pt) |
MY (1) | MY159135A (pt) |
NO (1) | NO2506868T3 (pt) |
NZ (2) | NZ703153A (pt) |
PL (2) | PL2506868T3 (pt) |
PT (2) | PT3326643T (pt) |
RS (1) | RS56957B1 (pt) |
SG (3) | SG181130A1 (pt) |
SI (1) | SI2506868T1 (pt) |
WO (1) | WO2011069164A2 (pt) |
ZA (1) | ZA201204874B (pt) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6263355A (ja) * | 1985-09-13 | 1987-03-20 | Hitachi Ltd | バツテリバツクアツプramのチエツク方法 |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
NZ628987A (en) | 2009-02-03 | 2015-11-27 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
US9050318B2 (en) | 2009-12-06 | 2015-06-09 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
AU2011274423B2 (en) | 2010-07-09 | 2016-02-11 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
EP3527218A1 (en) | 2011-06-10 | 2019-08-21 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
EA029045B1 (ru) * | 2011-07-08 | 2018-02-28 | Байоджен Хемофилия Инк. | Химерные и гибридные полипептиды фактора viii и способы их применения |
EP2737311B1 (en) * | 2011-07-25 | 2020-12-02 | Bioverativ Therapeutics Inc. | Assays to monitor bleeding disorders |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
LT2791160T (lt) | 2011-12-16 | 2022-06-10 | Modernatx, Inc. | Modifikuotos mrnr sudėtys |
NZ626945A (en) * | 2012-01-12 | 2016-10-28 | Biogen Ma Inc | Chimeric factor viii polypeptides and uses thereof |
PL2802668T3 (pl) * | 2012-01-12 | 2019-03-29 | Bioverativ Therapeutics Inc. | Sposoby zmniejszania immunogenności wobec czynnika krzepnięcia viii u pacjentów poddawanych leczeniu czynnikiem krzepnięcia viii |
KR20190094480A (ko) | 2012-02-15 | 2019-08-13 | 바이오버라티브 테라퓨틱스 인크. | 재조합 인자 viii 단백질 |
PT3564260T (pt) * | 2012-02-15 | 2023-01-18 | Bioverativ Therapeutics Inc | Composições de fator viii e métodos de produção e utilização das mesmas |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP3521321B1 (en) | 2012-04-11 | 2020-11-04 | Bioverativ Therapeutics Inc. | Methods of detecting glycosaminoglycans |
AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
EP4079316A1 (en) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
SG11201500045RA (en) * | 2012-07-11 | 2015-02-27 | Amunix Operating Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
WO2014018777A2 (en) | 2012-07-25 | 2014-01-30 | Biogen Idec Ma Inc. | Blood factor monitoring assay and uses thereof |
WO2014063108A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
EP2914293A4 (en) * | 2012-10-30 | 2016-04-20 | Biogen Ma Inc | METHOD OF USE OF FVIII POLYPEPTIDE |
WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
DK2956477T4 (da) * | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
SI2968477T1 (sl) * | 2013-03-15 | 2020-04-30 | Bioverativ Therapeutics Inc. | Polipeptidne formulacije faktorja VIII |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014190305A2 (en) | 2013-05-24 | 2014-11-27 | Biogen Idec Ma Inc. | Anti-gpiib/iiia antibodies or uses thereof |
TW201536811A (zh) * | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合fvii-xten分子及其用途 |
EA037962B1 (ru) * | 2013-06-20 | 2021-06-16 | Баксалта Инкорпорейтед | Способ и аппарат для фармакокинетической схемы дозирования лекарственного средства |
WO2014210547A1 (en) * | 2013-06-28 | 2014-12-31 | Biogen Idec Ma Inc. | Thrombin cleavable linker |
CN113831415A (zh) * | 2013-06-28 | 2021-12-24 | 比奥贝拉蒂治疗公司 | 具有xten的凝血酶可裂解连接子和其用途 |
EP3027224B1 (en) | 2013-07-31 | 2020-06-03 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子viii-xten融合物及其用途 |
EP4108254A1 (en) | 2013-08-14 | 2022-12-28 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
ES2900425T3 (es) | 2013-09-25 | 2022-03-16 | Bioverativ Therapeutics Inc | Métodos de inactivación vírica en columna |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
US20160289633A1 (en) | 2013-12-20 | 2016-10-06 | Biogen Ma Inc. | Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality |
BR122023020301A2 (pt) | 2014-01-10 | 2023-12-12 | Bioverativ Therapeutics Inc. | Uso de uma proteína quimérica compreendendo uma proteína fviii |
US20160347787A1 (en) | 2014-02-04 | 2016-12-01 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
WO2015148454A1 (en) * | 2014-03-28 | 2015-10-01 | Asklepios Biopharmaceutical, Inc. | Optimized and modified factor viii genes for gene therapy |
AU2015249452B2 (en) | 2014-04-25 | 2017-10-26 | Pfizer Inc. | Antibody-drug conjugates with high drug loading |
CA2964317C (en) | 2014-10-14 | 2021-10-05 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
WO2017070167A1 (en) | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
US11753461B2 (en) | 2016-02-01 | 2023-09-12 | Bioverativ Therapeutics Inc. | Optimized factor VIII genes |
EA201892347A1 (ru) | 2016-04-15 | 2019-04-30 | Баксалта Инкорпорейтед | Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов |
TW201739448A (zh) * | 2016-05-06 | 2017-11-16 | 安成生物科技股份有限公司 | 用於治療及/或預防血液相關疾病之方法及配方 |
US11046749B2 (en) | 2016-06-24 | 2021-06-29 | Mogam Institute For Biomedical Research | Chimera protein comprising FVIII and vWF factors, and use thereof |
BR112019002039A2 (pt) | 2016-08-05 | 2019-05-07 | Medimmune, Llc | anticorpos anti-o2 e uso dos mesmos |
CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
AU2017346488A1 (en) | 2016-10-19 | 2019-05-30 | Humabs Biomed Sa | Anti-O1 antibodies and uses thereof |
CN108239151B (zh) * | 2016-12-23 | 2020-07-03 | 海门晟斯生物制药有限公司 | 重组单链人FVIII-Fc融合蛋白及其应用 |
US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
CA3051862A1 (en) | 2017-01-31 | 2018-08-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
WO2019236739A1 (en) | 2018-06-05 | 2019-12-12 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
CA3110530A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
CA3144630A1 (en) | 2019-06-19 | 2020-12-24 | Bioverativ Therapeutics Inc. | Methods and compositions for treating hemophilia and low bone mineral density |
WO2023211315A1 (en) * | 2022-04-28 | 2023-11-02 | Joint Stock Company "Biocad" | Isolated nucleic acid that encodes fusion protein based on fviii-bdd and on heterologous signal peptide |
CN114989307B (zh) * | 2022-05-11 | 2023-08-01 | 华兰生物工程股份有限公司 | 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235881A (en) * | 1978-12-04 | 1980-11-25 | Cort Joseph H | Method for producing high potency factor VIII |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
WO1986006101A1 (en) | 1985-04-12 | 1986-10-23 | Genetics Institute, Inc. | Novel procoagulant proteins |
KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
EP0253870B1 (en) | 1986-01-03 | 1993-03-31 | Genetics Institute, Inc. | Method for producing factor viii:c-type proteins |
US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
US5610278A (en) | 1986-06-24 | 1997-03-11 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
CN1406249B (zh) | 2000-02-11 | 2010-06-16 | 默克专利股份有限公司 | 增加基于抗体的融合蛋白的循环半衰期 |
WO2001079442A2 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ATE386538T1 (de) * | 2001-02-05 | 2008-03-15 | Novo Nordisk Healthcare Ag | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden |
ES2500918T3 (es) | 2001-12-21 | 2014-10-01 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina e interferón beta |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
EP1444986A1 (en) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmaceutical preparation for the improved treatment of blood-clotting disorders |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
KR100912381B1 (ko) | 2003-06-19 | 2009-08-19 | 타녹스 인코퍼레이티드 | 응고 관련 질병을 치료하기 위한 조성물 및 방법 |
US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
LT1824988T (lt) | 2004-11-12 | 2017-10-25 | Bayer Healthcare Llc | Nukreipta į užduotą saitą fviii modifikacija |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1996220B2 (en) | 2006-03-06 | 2023-08-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
CA2647314A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
JP5448839B2 (ja) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
EP2185701A4 (en) | 2007-08-15 | 2011-03-02 | Amunix Operating Inc | COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES |
WO2009108806A1 (en) * | 2008-02-27 | 2009-09-03 | Novo Nordisk A/S | Conjugated factor viii molecules |
NZ628987A (en) | 2009-02-03 | 2015-11-27 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
CA2756197A1 (en) * | 2009-03-24 | 2010-09-30 | Bayer Healthcare Llc | Factor viii variants and methods of use |
GB0908515D0 (en) | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
US9050318B2 (en) | 2009-12-06 | 2015-06-09 | Biogen Idec Hemophilia Inc. | Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof |
EA029045B1 (ru) | 2011-07-08 | 2018-02-28 | Байоджен Хемофилия Инк. | Химерные и гибридные полипептиды фактора viii и способы их применения |
SI2968477T1 (sl) * | 2013-03-15 | 2020-04-30 | Bioverativ Therapeutics Inc. | Polipeptidne formulacije faktorja VIII |
JP6083911B2 (ja) | 2014-12-19 | 2017-02-22 | 花王株式会社 | 吸収性物品 |
-
2010
- 2010-12-06 US US13/513,424 patent/US9050318B2/en active Active
- 2010-12-06 HU HUE10835255A patent/HUE036233T2/hu unknown
- 2010-12-06 NZ NZ703153A patent/NZ703153A/en unknown
- 2010-12-06 MY MYPI2012002429A patent/MY159135A/en unknown
- 2010-12-06 NO NO10835255A patent/NO2506868T3/no unknown
- 2010-12-06 SG SG2012039640A patent/SG181130A1/en unknown
- 2010-12-06 EP EP10835255.0A patent/EP2506868B1/en active Active
- 2010-12-06 EP EP17194648.6A patent/EP3326643B1/en active Active
- 2010-12-06 BR BR112012013502A patent/BR112012013502A2/pt not_active Application Discontinuation
- 2010-12-06 CN CN2010800629507A patent/CN102791285A/zh active Pending
- 2010-12-06 AU AU2010325787A patent/AU2010325787B2/en active Active
- 2010-12-06 SI SI201031628T patent/SI2506868T1/en unknown
- 2010-12-06 CA CA2782424A patent/CA2782424C/en active Active
- 2010-12-06 PT PT171946486T patent/PT3326643T/pt unknown
- 2010-12-06 MX MX2016000039A patent/MX353233B/es unknown
- 2010-12-06 ES ES10835255.0T patent/ES2659888T3/es active Active
- 2010-12-06 KR KR1020127017595A patent/KR101770849B1/ko active IP Right Grant
- 2010-12-06 PT PT108352550T patent/PT2506868T/pt unknown
- 2010-12-06 EA EA201290443A patent/EA025416B1/ru not_active IP Right Cessation
- 2010-12-06 RS RS20180182A patent/RS56957B1/sr unknown
- 2010-12-06 PL PL10835255T patent/PL2506868T3/pl unknown
- 2010-12-06 CA CA3121739A patent/CA3121739A1/en active Pending
- 2010-12-06 JP JP2012542240A patent/JP5903048B2/ja active Active
- 2010-12-06 LT LTEP10835255.0T patent/LT2506868T/lt unknown
- 2010-12-06 ME MEP-2018-40A patent/ME02964B/me unknown
- 2010-12-06 MX MX2012006347A patent/MX336830B/es active IP Right Grant
- 2010-12-06 WO PCT/US2010/059136 patent/WO2011069164A2/en active Application Filing
- 2010-12-06 SG SG10201907152YA patent/SG10201907152YA/en unknown
- 2010-12-06 EP EP21161784.0A patent/EP3906937A1/en active Pending
- 2010-12-06 ES ES17194648T patent/ES2880038T3/es active Active
- 2010-12-06 PL PL17194648T patent/PL3326643T3/pl unknown
- 2010-12-06 EA EA201691109A patent/EA038618B1/ru unknown
- 2010-12-06 SG SG10201408049SA patent/SG10201408049SA/en unknown
- 2010-12-06 NZ NZ600709A patent/NZ600709A/en unknown
- 2010-12-06 DK DK10835255.0T patent/DK2506868T3/da active
-
2012
- 2012-06-06 IL IL220204A patent/IL220204B/en active IP Right Grant
- 2012-06-29 ZA ZA2012/04874A patent/ZA201204874B/en unknown
- 2012-06-29 CO CO12109855A patent/CO6561782A2/es unknown
-
2013
- 2013-03-11 US US13/793,783 patent/US9241978B2/en active Active
-
2015
- 2015-01-26 JP JP2015012409A patent/JP6062459B2/ja active Active
- 2015-12-09 US US14/964,289 patent/US20160199455A1/en not_active Abandoned
-
2016
- 2016-08-11 AU AU2016213822A patent/AU2016213822B2/en active Active
- 2016-10-26 JP JP2016209535A patent/JP6385410B2/ja active Active
-
2017
- 2017-11-15 JP JP2017220060A patent/JP6641340B2/ja active Active
- 2017-11-30 AU AU2017268648A patent/AU2017268648B2/en active Active
-
2018
- 2018-01-24 HR HRP20180135TT patent/HRP20180135T1/hr unknown
- 2018-02-14 CY CY20181100182T patent/CY1119919T1/el unknown
- 2018-07-25 IL IL260769A patent/IL260769B/en active IP Right Grant
- 2018-10-11 HK HK18113027.0A patent/HK1253887A1/zh unknown
-
2019
- 2019-02-07 US US16/270,302 patent/US11266720B2/en active Active
- 2019-04-29 AU AU2019202969A patent/AU2019202969A1/en not_active Abandoned
- 2019-11-07 JP JP2019202433A patent/JP2020019821A/ja not_active Withdrawn
-
2021
- 2021-05-07 AU AU2021202912A patent/AU2021202912A1/en active Pending
- 2021-06-28 HR HRP20211010TT patent/HRP20211010T1/hr unknown
- 2021-07-07 CY CY20211100615T patent/CY1124888T1/el unknown
-
2022
- 2022-01-28 US US17/587,941 patent/US20220265780A1/en active Pending
- 2022-02-14 JP JP2022020759A patent/JP7244688B2/ja active Active
-
2023
- 2023-03-09 JP JP2023036392A patent/JP2023071969A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012013502A2 (pt) | "polipeptídeos quiméricos e híbridos de fator viii-fc, e métodos de uso dos mesmos". | |
BR112013000650A2 (pt) | poliptídeos de fator ix e métodos de uso dos mesmos. | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
CL2016000344A1 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
BR112013003248A2 (pt) | "macrociclo peptidomimético e seus usos" | |
ECSP11011054A (es) | Péptidos antivirales terapéuticos | |
BR112014019901A2 (pt) | proteínas de fator viii recombinante | |
WO2013152351A3 (en) | Fusion polypeptides and methods of use thereof | |
BR112013009083A8 (pt) | anticorpos humanos de oncostatin m e métodos de uso | |
MX351353B (es) | Composiciones farmacéuticas basadas en shk y métodos para prepararlas y usarlas. | |
WO2011034659A3 (en) | Advantageous mu-opiate receptor peptide compounds | |
BR112012020833A2 (pt) | tetrapeptídeos cíclicos e aplicações terapêuticas destes | |
RU2008136668A (ru) | Пептиды, обладающие нейротропной активностью | |
GB0818080D0 (en) | Immunogenic peptides | |
ITMI20110764A1 (it) | Procedimento per l'impiego di un impianto di iniezione | |
EA202092566A1 (ru) | Фактор ix полипептиды и способы их использования | |
UA35660U (en) | Use of antihomotoxic preparations as cytoprotectors | |
RU2010147073A (ru) | Химерный пептид для лечения фиброаденомы молочной железы | |
UA33215U (ru) | Применение цитокиноподобного полипептида емар-іі как средства, оказывающего противоопухолевое действие на рост карциномы предстательной железы | |
AU318176S (en) | Manifold insulator for Nissan RB30 series. | |
UA37933U (ru) | Применение амкесола как вещества с противовоспалительными свойствами | |
AU319805S (en) | Manifold insulator 3 | |
AU319804S (en) | Manifold insulator 2 | |
AU319800S (en) | Manifold insulator 4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BIOGEN HEMOPHILIA INC. (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: BIOVERATIV THERAPEUTICS INC. (US) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: BIOVERATIV THERAPEUTICS INC. (US) |